12 months from date of receipt / reconstitution, 2 to 8 °C as supplied
应用 | 稀释度 |
---|---|
ELISA | 1.221-5000 ng/ml |
Durvalumab is an immunotherapy for cancer. It is a human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody that blocks the interaction of programmed cell death ligand 1 (PD-L1) with the PD-1 (CD279).
Immobilized human PD-L1 at 0.5 μg/ml (50 μL/well) can bind to Durvalumab with a linear range of 1.221 ng/ml-5 μg/ml.